Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Temozolomide Stories

2009-03-09 13:53:12

German and Swiss scientists say they have used the combination of two drugs to achieve a substantial improvement in the treatment of certain brain tumors. The researchers led by Professor Dr. Ulrich Herrlinger of the University of Bonn treated 39 patients who had been diagnosed with a gliablastoma. The patients -- treated with a combination of temozolomide and lomustine -- survived on average 23.1 months, while with the standard therapy the mean would have been 14.6 months, the researchers...

2009-03-09 07:00:00

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the...

2009-03-05 07:00:00

Schering-Plough Receives EU and US Approvals for Intravenous Formulation of Temozolomide As Well As EU Approval for Oral Temozolomide Sachet Presentation KENILWORTH, N.J., March 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug. Temozolomide is marketed as TEMODAL(R) in the EU and as...

2009-02-17 06:00:00

TSX: BMR TORONTO, Feb. 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update today on the ongoing Phase III GLASS-ART Trial testing Neuradiab(R) in the most advanced form of brain cancer (glioblastoma). Bradmer also announced that its Board of Directors has recommended a review of strategic options in light of performance, market conditions and new projections of site initiation and patient enrollment from the Company's clinical research organization (CRO)....

2009-01-19 07:00:00

Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug for treating stage IV malignant melanoma that can increase median overall survival when compared with standard of care dacarbazine (Bedford Laboratories' DTIC-Dome,...

2008-12-18 15:30:00

NEEDHAM, Mass. and NEW YORK, Dec. 18 /PRNewswire-FirstCall/ -- Celldex Therapeutics (Nasdaq: CLDX) and Pfizer Inc. (NYSE: PFE) today announced plans to amend the ongoing ACT III clinical trial involving the investigational compound, CDX-110. ACT III is a randomized open-label, two-arm, Phase 2b/3 trial comparing CDX-110 combined with temozolomide to temozolomide alone in patients with newly diagnosed Glioblastoma Multiforme (GBM). Only the Phase 2b portion of the trial has been open to...

2008-12-08 07:00:00

Schering-Plough Receives CHMP Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL Sachet Presentation -- Providing Potential New Treatment Options for EU Patients with Certain Primary Brain Tumors KENILWORTH, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of the...

2008-12-08 07:00:00

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United...

2008-12-03 05:30:00

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced an exclusive, binding letter of intent with EIP Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republic of Northern Cyprus. EIP has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price in...

2008-12-01 07:00:00

TSX: BMR TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it has been granted European Patent, # 1351713, entitled "Anti-Tenascin Monoclonal Antibody Therapy For Lymphoma." The claims cover the use of the Company's lead product for Glioblastoma, 131-Iodine (131I) Neuradiab(TM) candidate (monoclonal antibody 81C6), which binds to tenascin for the...